BrightPath Biotherapeutics Co.Ltd. (4594) AI Stock Analysis

• Market Cap: ¥3.74B
• Dividend Yield: N/A
• Average Volume (3M): 297.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: 1473.61%
• EPS Growth: 22.61%
• Country: JP
• Employees: 42
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -3.82
• Shares Outstanding: 93,441,300
• 10 Day Avg. Volume: 229,670
• 30 Day Avg. Volume: 297,606
• PEG Ratio: 0.54
• Price to Book (P/B): 6.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ¥40.00 ▲(0.00%Upside)

BrightPath Biotherapeutics faces significant financial challenges with consistent net losses and negative cash flow, which weigh heavily on its stock score. Technical indicators provide a neutral outlook, while valuation metrics are unattractive due to a negative P/E ratio and lack of dividends. The absence of recent earnings call or notable corporate events keeps the focus on financial and technical aspects.

BrightPath Biotherapeutics Co.Ltd. Business Overview & Revenue Model

Company Description

BrightPath Biotherapeutics Co., Ltd. (4594) is a biotechnology company primarily engaged in the research and development of innovative immunotherapy treatments. The company focuses on developing novel cancer immunotherapies that leverage the body's immune system to target and eliminate cancer cells. Their core products include personalized peptide vaccines and other immunotherapy agents aimed at addressing various types of cancer.

How the Company Makes Money

BrightPath Biotherapeutics generates revenue through the development and commercialization of its proprietary immunotherapy treatments. The company's revenue model is primarily based on licensing agreements, research and development collaborations, and the eventual commercialization of its drug candidates. Key revenue streams include milestone payments and royalties from partnerships with pharmaceutical companies. Additionally, BrightPath may receive funding from government grants and research subsidies, which support its ongoing clinical trials and research initiatives.

BrightPath Biotherapeutics Co.Ltd. Financial Statement Overview

Summary

BrightPath Biotherapeutics is facing significant financial challenges, with ongoing negative EBIT, EBITDA, and net income figures. While the company has a strong equity base and low leverage, persistent losses and negative cash flow are concerning for operational sustainability.

Income Statement

BrightPath Biotherapeutics has been experiencing significant challenges with consistent negative EBIT, EBITDA, and net income figures over the years. Despite a sharp increase in total revenue from 2024 to 2025, the company is still operating at a loss. Gross profit margin improved in 2025, but the net profit margin remains deeply negative, indicating ongoing operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company's equity ratio is strong, indicating a robust equity base relative to total assets. However, the company has been consistently operating with net losses, which could affect equity over time. The debt-to-equity ratio is low, reflecting minimal leverage and a conservative capital structure, which is a positive aspect. However, persistent losses could threaten the long-term sustainability of this structure.

Cash Flow

BrightPath Biotherapeutics has a negative free cash flow, which is concerning for its liquidity and operational funding. Operating cash flow is also negative, indicating that the company is not generating sufficient cash from its core operations to cover expenses. The reliance on financing cash flow to bridge cash deficits suggests potential sustainability issues if the trend persists.

Breakdown
TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
118.00K	1.13M	72.00K	5.28M	15.41M	2.50M
	Gross Profit
-511.00K	1.10M	-341.00K	3.38M	12.09M	1.36M
	EBIT
-1.20B	-1.16B	-1.16B	-1.47B	-1.48B	-1.73B
	EBITDA
-1.20B	-1.15B	-1.17B	-1.47B	-1.45B	-1.65B
	Net Income Common Stockholders
-1.21B	-1.15B	-1.17B	-1.49B	-1.48B	-1.72B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.30B	810.47M	1.06B	1.53B	2.31B	3.27B
	Total Assets
1.43B	1.12B	1.23B	1.70B	2.77B	3.75B
	Total Debt
500.00M	25.00M	112.50M	0.00	87.50M	0.00
	Net Debt
-796.94M	-785.47M	-944.86M	-1.53B	-2.22B	-3.27B
	Total Liabilities
655.82M	195.62M	251.27M	133.91M	239.73M	211.79M
	Stockholders Equity
772.75M	924.99M	978.99M	1.57B	2.53B	3.54B
Cash Flow		Free Cash Flow
8.98M	-1.25B	-1.16B	-1.21B	-1.53B	-1.81B
	Operating Cash Flow
8.98M	-1.25B	-1.16B	-1.20B	-1.51B	-1.77B
	Investing Cash Flow
0.00	-1.37M	-7.65M	-1.76M	-17.57M	-36.21M
	Financing Cash Flow
0.00	1.00B	690.96M	432.10M	569.23M	2.05B

BrightPath Biotherapeutics Co.Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 40.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4594, the sentiment is Neutral. The current price of 40 is above the 20-day moving average (MA) of 39.80, above the 50-day MA of 39.52, and below the 200-day MA of 45.83, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.37 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4594.

BrightPath Biotherapeutics Co.Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	73 Outperform	¥4.79B	19.22		―	18.71%	33.40%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
2342	50 Neutral	¥2.60B	―		1.95%	3.46%	59.89%
4594	45 Neutral	¥3.74B	―		―	1473.61%	22.61%
4881	38 Underperform	¥4.62B	―		―	1056.04%	21.63%
4591	37 Underperform	¥4.06B	―		―	-96.64%	8.92%
4598	28 Underperform	¥6.95B	―		―	―	-11.46%